Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

Researchers identify markers of lymphoma recurrence

Follicular Lymphoma (FL) is a type of blood cancer and a form of non-Hodgkin's lymphoma. Thanks to new treatment breakthroughs, about 80% of FL patients have a survival rate of more than 10 years.

31 Mar 2026

Rare cancer gene found in sperm donor sparks European regulatory concerns

A case in which a sperm donor was later found to be carrying a cancer-causing pathogenic variant in his gametes has highlighted the problems of regulating gamete donation at European and international level, the annual conference of the European Society of Human Genetics will hear today (Saturday).

23 May 2025

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies.

8 May 2025

New test could predict life-threatening side effects of cancer immunotherapy

Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs.

10 Mar 2025

How the FDA lets chemicals pour into America’s food supply

Joseph Shea, who sells athletic wear in Myrtle Beach, South Carolina, wonders and worries about the food he eats.

10 Mar 2025

Future of cancer coverage for women federal firefighters uncertain under Trump

It took nearly three years to win presumptive workers' compensation coverage for breast, cervical, and other cancers that firefighters who work for federal agencies may develop because of hazardous exposures on the job.

28 Feb 2025

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the importance of patient advocacy.

3 Feb 2025

Key information to consider before getting breast implants

Should I get breast implants? Should they be saline or silicone? Which style? How much monitoring is needed after surgery?

31 Jan 2025

Houston Methodist researchers join national consortium to develop herpesvirus vaccine

Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government's Advanced Research Projects Agency for Health (ARPA-H) to develop a vaccine against two of the most common and destructive strains of herpesviruses that latently infect a majority of Americans and can lead to acute infections, multiple forms of cancer, autoimmune disease and birth defects.

3 Oct 2024

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

Researchers comprehensively evaluated the impact of pesticide use on cancer development in the United States.

29 Jul 2024

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

High BMI in late teens linked to higher risk of 17 different cancers later in life

Men who are overweight or obese at age 18 have a higher risk of 17 different cancers later in life. This has been shown in a study at the University of Gothenburg.

6 Nov 2023

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Researchers examined the association between moderate alcohol intake and specific cancer risks.

21 Aug 2023

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair."

13 Jun 2023

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

The Pediatric Cancer Research Foundation, a nonproﬁt focused on transforming pediatric cancer care by accelerating research breakthroughs, today announced the 19 recipients of its 2023 research grants.

26 May 2023

Formerly incarcerated persons have higher health risks than the general population

In 2012, Michael Cruz exercised a lot. Four years into a 15-year prison sentence, this was one of the only things he had, he says, until he noticed a numb, tingling sensation in one of his toes while working out.

3 Apr 2023

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword. While the drugs are highly effective at killing cancer cells, they are also notorious for killing healthy cells in the body.

27 Jan 2023

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.

9 Jan 2023

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022